Inebilizumab
Inebilizumab is a monoclonal antibody designed for the treatment of neuromyelitis optica, a rare neurological condition. It is marketed under the brand name Uplizna.
Mechanism of Action[edit | edit source]
Inebilizumab works by binding to a specific protein, CD19, found on the surface of B cells. By doing this, it helps to reduce the number of B cells in the body, which are believed to play a key role in the development of neuromyelitis optica.
Uses[edit | edit source]
Inebilizumab is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
Side Effects[edit | edit source]
Common side effects of Inebilizumab include urinary tract infection, back pain, joint pain, headache, and high blood pressure. Serious side effects can include infection, liver problems, and depression.
History[edit | edit source]
Inebilizumab was approved by the Food and Drug Administration (FDA) in June 2020, making it the second drug approved for the treatment of NMOSD.
References[edit | edit source]
See Also[edit | edit source]
Inebilizumab Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD